

Clinical trials of rivaroxaban + aspirin

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|------------------------------|
| rivaroxaban + aspirin vs aspirin | | | |
| COMPASS (rivaroxaban + aspirin) , 2017 [NCT01776424] n=9152/9126 follow-up: 23 months | rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily) versus aspirin 100 mg once daily | Patients With Coronary or Peripheral Artery Disease | Parallel groups double-blind |

More details and results :

- anticoagulant for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q481>
- direct oral anticoagulant (DAO) for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q706>
- direct factor Xa inhibitors for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q707>
- anticoagulant for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q709>

References

COMPASS (rivaroxaban + aspirin), 2017:

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfeld J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakka Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017;377:1319-1330 [28844192]

Entry terms: rivaroxaban, Xarelto, BAY 59-7939,